CLSDClearside BiomedicalCLSD info
$1.02info0.99%24h
Global rank4140
Market cap$63.66M
Change 7d0.00%
YTD Performance-14.29%
SP500 benchmarkUnderperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Clearside Biomedical (CLSD) Stock Overview

    Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. Clearside Biomedical, Inc. has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. The company was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

    CLSD Stock Information

    Symbol
    CLSD
    Address
    900 North Point ParkwayAlpharetta, GA 30005United States
    Founded
    -
    Trading hours
    -
    Website
    https://clearsidebio.com
    Country
    πŸ‡ΊπŸ‡Έ United States
    Phone Number
    678 270 3631

    Clearside Biomedical (CLSD) Price Chart

    -
    Value:-

    Clearside Biomedical Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $1.02
    N/A
    Market Cap
    $63.66M
    N/A
    Shares Outstanding
    62.41M
    N/A
    Employees
    36.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    Β© 2024 Topstocks.org